- Home
- CGON
CGON
CG ONCOLOGY INC
as 04-17-2025 1:33pm EST
Stocks
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 1.3B | IPO Year: | 2024 |
| Target Price: | $65.11 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.80 - $46.99 | Next Earning Date: | 05-08-2025 |
| Revenue: | $1,139,000 | Revenue Growth: | 461.08% |
| Revenue Growth (this year): | -33.32% | Revenue Growth (next year): | 16237.24% |
Stock Insider Trading Activity of CG ONCOLOGY INC (CGON)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| POST LEONARD E | CGON | Director | Mar 17 '25 | Sell | $28.00 | 1,000 | $28,000.00 | 0 | |
| POST LEONARD E | CGON | Director | Feb 18 '25 | Sell | $28.61 | 1,000 | $28,610.00 | 0 |
Latest CG ONCOLOGY INC News
CGON Breaking Stock News: Dive into CGON Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Scotiabank Initiates CG Oncology at Sector Perform With $23 Price Target
The Wall Street Journal
6 days ago
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
Zacks
17 days ago
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade
GlobeNewswire
17 days ago
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
Zacks
17 days ago
Company News for Mar 31, 2025
MT Newswires
17 days ago
CG Oncology Files Mixed Shelf
Simply Wall St.
19 days ago
CG Oncology Full Year 2024 Earnings: Misses Expectations
GlobeNewswire
20 days ago
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
Compare CGON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CGON CG ONCOLOGY INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.